CAPLYTA Shows Stronger Remission Results in Phase 3 MDD Data, JNJ Says [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
On January 16, Johnson & Johnson (NYSE:JNJ) shared results from a new analysis of Phase 3 data showing that CAPLYTA (lumateperone), when used alongside an antidepressant, delivered significantly higher remission rates in adults with major depressive disorder compared with placebo plus an antidepressant after six weeks. The company also said the benefits held up over time, with continued improvement observed through six months in an open-label extension study. These results were included in one of 11 abstracts from Johnson & Johnson's neuropsychiatry portfolio presented at the 64th Annual Meeting of the American College of Neuropsychopharmacology, held January 12 to 15 in Nassau, Bahamas. Even with other corporate moves in the pipeline, including plans to spin off its orthopedics business, Johnson & Johnson's main engine is still its ability to develop new medicines and advanced medical technology. Its pipeline and commercial products cover a wide set of areas, including immunology
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Stock market today: Dow, S&P 500, Nasdaq futures sink as Trump targets allies with tariff threat over Greenland [Yahoo! Finance Canada]Yahoo! Finance Canada
- [Latest] Global Hydrogel Face Mask Market Size/Share Worth USD 560.2 Million by 2034 at a 10.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) [Yahoo! Finance]Latest
- Zacks Investment Ideas feature highlights: Netflix, Intel and Johnson & Johnson [Yahoo! Finance]Yahoo! Finance
- 3 Dividend Stocks to Own No Matter Where the Market Moves in 2026 [Yahoo! Finance]Yahoo! Finance
- Hernia Repair Devices Market Report 2026: $6.57 Bn Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts | Astute Analytica [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 10/14/25 - Beat
JNJ
Sec Filings
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- 12/11/25 - Form 4
- JNJ's page on the SEC website